lorcaserin (Belviq®)


Indications for Prior Authorization

  • Indicated as an adjunct to a reduced calorie diet and exercise for weight management.

Patients must meet the following criteria for the indications above:

  • BMI > 30 kg/m2 AND
  • At least one comorbid condition confirmed by chart note documentation/prescription data:
    • Hypertension
    • Diabetes
    • Hyperlipidemia

The following conditions do not meet the criteria for use as established by the WHA P&T Committee:

  • All non-FDA approved indications
  • Patients who are pregnant or may become pregnant during therapy


  • Lorcaserin 10mg every 12 hours orally
  • Discontinue if weight loss >5% not achieved in 12 weeks


  • Initial approval: 12 weeks
  • Renewal: 6 months
  • Renewal requires chart note documentation of reduction in patient weight


Last review date: January 7, 2013

WHA is closely monitoring the Coronavirus Disease 2019 (COVID-19). Learn more about COVID-19.